Epidemiology

Parkinson's Disease Epidemiology Forecast Report 2019-2023 and 2023-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024
Health, Pharmaceutical, Male, Parkinson's disease, EU4, Epidemiology, Disease, Female, Pharmaceutical industry

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Key Points: 
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
  • The US accounted for nearly 45% of the total diagnosed prevalent cases of Parkinson's disease in the 7MM.
  • Germany accounted for the highest number of Parkinson's disease cases, with nearly 454,448 cases, while Italy accounted for the least diagnosed prevalent cases of Parkinson's disease in 2022.
  • The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease.

Kappa Delta Elizabeth Winston Lanier Award Presented to The ANCHOR Group for Improving Quality of Care for Young Patients With Pre-Arthritic Hip Conditions

Retrieved on: 
Friday, February 2, 2024
Deformity, BBC, Surgeon, Classification, Research, MD, OA, DDH, Patient, Pain, Safety, Groin, Diagnosis, Adolescence, Orthopedic surgery, Hip, FAI, Femoroacetabular impingement, PAO, Epidemiology, Motion, Quality of life, Data, DSM-IV codes, LCPD, Legg–Calvé–Perthes disease, Health, Data collection, Nursing

This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.

Key Points: 
  • This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.
  • "In the early 2000s, the orthopaedic community lacked an understanding of pre-arthritic hip disease diagnoses and treatments.
  • "Over the past 20 years, access to quality care for young patients with pre-arthritic hip disease has markedly improved" said Dr. Clohisy.
  • "We now have surgeons and health care teams who can deliver a comprehensive approach to manage the full spectrum of pre-arthritic hip disease.

Global Consulting Firm J.S. Held Releases Expert Insights on Carbon Management: Issues in Greenhouse Gas Management

Retrieved on: 
Wednesday, January 31, 2024
Carbon, Biophysical environment, ESG, Pressure, European, Consultant, Data management, Non-governmental organization, Environment, Climate change, GHG, Epidemiology, Environment, health and safety, Risk, Environmental Health (journal), Climate, Toxicology, EHS, Organization, Renewable energy

JERICHO, N.Y., Jan. 31, 2024 /PRNewswire-PRWeb/ -- Global consulting firm J.S. Held announces the publication of an insightful article on Carbon Management written by one of the sustainability experts in J.S. Held's Environmental, Health, and Safety (EHS) practice. The article delves deeply into the complexities of Carbon Management, discussing its likely impacts on organizations and providing a high-level strategic checklist for responding to new carbon management requirements effectively, which is of value to all industries and companies facing demand for greater transparency of environmental performance.

Key Points: 
  • Held's sustainability expert unveils crucial insights on the forthcoming 2024 carbon reporting regulations and developing carbon strategies regarding climate change and greenhouse gas issues.
  • Held announces the publication of an insightful article on Carbon Management written by one of the sustainability experts in J.S.
  • The article "Carbon Management: Issues in Greenhouse Gas Management" discusses the growing complexity surrounding carbon management and greenhouse gas (GHG) reduction for companies across various industries.
  • To gain deeper insights into the impact of Carbon Management regulations and to explore more ways to develop carbon strategies, please read the full article here: https://www.jsheld.com/insights/articles/carbon-management-issues-in-gre... .

Jennifer Rider Appointed ConcertAI Head of Real-World Evidence Services

Retrieved on: 
Tuesday, January 30, 2024
Real-World Evidence, Abstract, Interview, Oncology, Research, AI, Clinical Cancer Research, Public, Flexner Report, FDA, Publication, Public health, Aetion, RCT, RWE, Harvard University, Epidemiology, MPH, Doctor of Science, Harvard Medical School, Drug development, Health, Doctor of Philosophy, University, University of Wisconsin–Madison, RWD

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer Rider, ScD, MPH, as the leader of the company's Real-World Evidence Services, focusing on regulatory applications of RWD as part of registration trials, breakthrough designation solutions post-approval studies, and regulatory registries. 

Key Points: 
  • Dr. Rider has over 20 years of experience in cancer epidemiology and real-world evidence research.
  • She first joined ConcertAI in 2020, moving from there to lead Aetion's Oncology Center of Excellence.
  • "Real-world evidence has taken on a more formal role in regulatory decision-making with the FDA's formalization of their guidance late last year ," said Jeff Elton, PhD, CEO of ConcertAI.
  • To hear more from Jennifer directly, listen to her interview on the latest episode of The ConcertAI Podcast here .

Adolescent and Young Adult (AYA) Cancer Experts Unite to Form First-of-its-Kind Consortium

Retrieved on: 
Tuesday, January 30, 2024
Adolescence, Health, Patient, Research, MD, Roswell Park, Knowledge, Survival, RWJBarnabas Health, Epidemiology, Consortium, University, Biomedical sciences, Oncology, Lymphoma, MBA, Cancer, Young adult, AYA, Cooper University Hospital, Master of Science, LRF, Diagnosis, Estate (law), Pharmaceutical industry

NEW YORK, Jan. 30, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – has announced the formation of its Adolescent and Young Adult (AYA) Lymphoma Consortium.

Key Points: 
  • In addition, the AYA Lymphoma Consortium and its membership will seek to support LRF's #EraseLymphoma initiative and raise awareness of the Foundation's AYA patient education efforts.
  • Both Dr. Evens and Dr. Kelly are globally recognized lymphoma researchers with a unique interest in the AYA patient population.
  • "There is a critical need to study lymphomas that occur in adolescents and young adults (AYA)," said Dr. Evens, co-chair of the AYA Lymphoma Consortium.
  • Other members of the AYA Lymphoma Consortium executive committee include pediatric oncologists, adult oncologists, laboratory and translational cancer researchers, epidemiologists, health services, survivorship, and quality of life experts from top institutions across the world.

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Retrieved on: 
Thursday, January 25, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Entrepreneurship, Chiron Corporation, MD, Influenza, Novartis, Global health, GSK, University, Diagnosis, Epidemiology, CMO, Doctor of Philosophy, Vaccine, GSK plc, Preventive healthcare

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer.
  • Dr. Groth joins Osivax as the company advances the development of its lead candidate, OVX836, a best-in-class broad-spectrum influenza vaccine candidate currently being evaluated in several Phase 2 clinical trials.
  • Dr. Groth takes over from Dr. Willems, whose contribution has been instrumental in advancing Osivax’ clinical strategy.
  • Nicola Groth holds a Doctor of Medicine and a PhD in Hygiene and Preventive Medicine from the University of Siena, Italy.

Harvard Pilgrim Health Care Institute Appoints New President

Retrieved on: 
Thursday, January 11, 2024
Epidemiology, Internal medicine, Therapy, Research, Pediatrics, Health, Health equity, Tufts Health Plan, Coral, Harvard Medical School, TIDE, Harvard Pilgrim Health Care, Division, Public health, NIH, Conditional sentence, Child, Harvard University, Master of Science, Chronic condition, MPH

CANTON, Mass., Jan. 11, 2024 /PRNewswire/ -- Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, today announced that Emily Oken, MD, MPH, has been appointed the new president of the Harvard Pilgrim Health Care Institute, following a nation-wide search. As part of her new role, Dr. Oken will also serve as chair of Harvard Medical School's Department of Population Medicine at the Harvard Pilgrim Health Care Institute.

Key Points: 
  • CANTON, Mass., Jan. 11, 2024 /PRNewswire/ -- Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, today announced that Emily Oken , MD, MPH, has been appointed the new president of the Harvard Pilgrim Health Care Institute, following a nation-wide search.
  • As part of her new role, Dr. Oken will also serve as chair of Harvard Medical School's Department of Population Medicine at the Harvard Pilgrim Health Care Institute.
  • Chan School of Public Health, and the Harvard Pilgrim Health Care Institute.
  • She is a professor of population medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute.

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Retrieved on: 
Monday, January 8, 2024
Commercial, Boehringer Ingelheim, DNA, Cancer, Investment, Novartis, SVP, Fermentation, Beam, Atlas, Kite Pharma, RNA interference, Sensible, Drug discovery, AbbVie, Invention, Biotechnology Innovation Organization, Eli Lilly, MBA, HIV, Merck, Therapy, Creativity, Epidemiology, RNA, GSK plc, DARPA, Process, WARF, Johnson & Johnson, Movement, Ginkgo Bioworks, Novo Nordisk, AI, Atlas Venture, AAV, Patient, Medicine, Synthetic biology, Senior, M28, Acquisition, BIO, MD, Doctor of Philosophy, Eli Lilly and Company, Hematology, Growth, Avantor, Infection, Pharmaceutical industry

BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.

Key Points: 
  • BOSTON, Jan. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the formation of its new Biopharma Advisory Board.
  • "The discovery and development of new medicines is critically important and incredibly challenging," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "I'm excited to welcome this incredible deep bench of wisdom and creativity to the Ginkgo family," said Jennifer Wipf, SVP & Head of Commercial at Ginkgo Bioworks.
  • Now more than ever, the speed of drug discovery and development is important," said Norbert Bischofberger, Ginkgo Biopharma Advisory Board member.

Frazier Life Sciences Strengthens Investment Team with Addition of Lin Mu, M.D., MBA as Senior Associate

Retrieved on: 
Thursday, January 4, 2024
Yale University, Conference, Research, Economics, Denison University, Science, MBA, University, PALO, Medicine, Growth, University of Cambridge, FLS, Epidemiology

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.

Key Points: 
  • PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Frazier Life Sciences (FLS), a longstanding venture capital firm investing in innovative biopharmaceuticals, proudly welcomes Lin Mu, M.D., MBA as a senior associate based in the Palo Alto office to its team of investment professionals.
  • These valuable skills position him as a strong addition to FLS, enhancing the firm's capability to continue growing its venture investing.
  • "We believe Lin's background is ideally suited for our mission at Frazier Life Sciences.
  • "Lin will play an important role in supporting our continued efforts to grow and evolve the Frazier Life Sciences' investment strategies."

Global Human African Trypanosomiasis (Sleeping Sickness) Market Research Report 2023: Historical Market Revenue Data 2020-2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 2, 2024
Health, Infectious Diseases, Trypanosomiasis, Non-governmental organization, Research, Male, Mortality, Fly, Disease, ESG, Sleep, Blood, Human, USD, COVID-19, Parasitism, Trypanosoma brucei, African trypanosomiasis, Patient, Sickness, HAT, Female, Epidemiology, Pharmaceutical industry

The "Sleeping Sickness - Human African Trypanosomiasis (HAT) Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sleeping Sickness - Human African Trypanosomiasis (HAT) Market" report has been added to ResearchAndMarkets.com's offering.
  • The market for sleeping disorders will be thoroughly covered in the current report.
  • The epidemiology, geographical markets, and market trends for sleeping sickness are examined in this paper.
  • This study will highlight the present sleeping sickness market and provide a thorough analysis of the market's competitive landscape.